BG98678A - Antiasthma medicament - Google Patents

Abstract

An anti-asthmatic drug, characterized in that it contains the following compounds in mg: atropinsulphate 0.25-2.00; papaverine hydrochloride from 30.00 up to 200.00; pure caffeine from 30.00 to 250.00; ergotamintartrate 0.25-2.00; zinc sulphate from 10.00 to 400.00 and sex hormone from 0.25 to 5.00.

Description

The invention relates to an anti-asthmatic drug for use in human medicine for the treatment of bronchial asthma and asthmatic bronchitis.

Technology level ____

A number of medicines are known to treat bronchial asthma and asthmatic bronchitis.

Xanthines are known for their stimulating effect on breathing and for the relief of bronchospasms. / 1 / There are also known combinations thereof with other drugs which show predominantly preventive and prophylactic action. / 2 /

Atropine sulfate is known as an antimuscarinic agent and its use in asthma.

Papaverine hydrochloride is known as an indisputable antispasmodic. It eliminates bronchial spasms and soothes breathing center and cough. / 1 /

Ergotamine is known to be a sympatholytic (1) and its specific effect in congestive conditions of the lung due to vasoconstrictive action on bronchial joints.

All of these drugs influence certain moments of the disease's symptoms without interrupting its development.

Corticosteroid preparations are also known as drugs used to treat bronchial asthma and asthmatic bronchitis / 1 / The disadvantages are that they can lead to manifestations of drug hypercorticism - obesity, arterial hypertension, osteoporosis, gastric and duodenal. the patient becomes completely dependent on exogenous corticosteroids upon initiation of treatment, and although his condition improves to some extent, new attacks are not prevented.

yyayamalv «yy &

if B-.H ^ A · ^} ^ W ^ j ^ - ^uV * «No.TlT ^ iti7> ^^ Υ ^ -Ιτλ ^ ί ^ MWi ^ iMiBm

Object of the invention

The object of the invention is to provide an anti-asthmatic drug that replicates the onset of the disease and results in prolonged remission over the years ie. to a practical cure, while not showing the severe side effects of corticosteroids.

SUMMARY OF THE INVENTION

The task is solved by creating an anti-asthmatic drug that contains atropine sulfate, papaverine hydrochloride, caffeine, ergotamine tartrate, zinc sulfate and sex hormones in the following quantitative ratios

atropine sulfate 0.25 - 1.00mg papaverine hydrochloride 30.00 - 200,00mg the caffeine is pure 30.00 - 250,00mg ergotamine tartrate 0.25 - 2.00mg zinc sulfate 10,00 - 220,00mg hormones 0.25 - 1.00mg

In cases where the drug is administered to female patients, female sex hormone oestrone is included in the combination. When administered to male patients, the hormone is methandienone.

The combination of active substances of the invention is suitable for the preparation of pharmaceutical forms using conventional pharmaceutical auxiliaries and carriers.

Advantages

The advantages of the agent according to the invention are:

Controls asthmatic attacks for 30-40 min.

Prevents new onset of distressing asthmatic breathing and subsequent asthmatic attacks for a period of 10 years or more, while being well tolerated and showing no severe side effects and complications of corticosteroids.

The following examples illustrate the invention without limitation.

EXAMPLE 1

Atropine sulfate 0.25 mg Papaverine hydrochloride 40.00 mg Caffeine is pure 50.00 mg Ergotamine tartrate 0.25 mg Zinc sulphate 40.00 mg Methandrostenol 1.00 mg

EXAMPLE 2

Atropine sulfate 1.00 mg Papaverine hydrochloride 100.00 mg Caffeine is pure 100.00 mg Ergotamine tartrate 1.00 mg Zinc sulphate 200,00 mg Methandrostenol 5.00 mg

EXAMPLE 3

Atropine sulfate

0.25 mg

Papaverine hydrochloride

40.00 mg

Caffeine is pure

Ergotamine tartrate

0.25 mg

Zinc sulphate

400,00 mg

Diethylstilbestrol propionate

0.25 mg

EXAMPLE 4

Atropine sulfate

1.00 mg

Papaverine hydrochloride

100.00 mg

• · · · ·

100.00 mg

Caffeine is pure

Ergotamine tartrate

Zinc sulphate

Diethylstilbestrol propionate

REFERENCES

1.00 mg

200,00 mg

1.00 mg

1. Martindale 1989

2. BE 903 065

3. J.W. Paterson and R. A. Tarala, Med.J.Aust., 1985,143,390

Claims (3)

Patent Claims An anti-asthmatic drug comprising atropine sulfate, papaverine hydrochloride, caffeine pure, ergotamine tartrate, zinc sulfate and sex hormones in the following quantitative proportions atropine sulfate 0.25 mg - 1.00 mg papaverine hydrochloride 30.00 mg - 200,00 mg the caffeine is pure 30.00 mg - 250,00 mg ergotamine tartrate 0.25 mg - 2.00 mg zinc sulfate 10.00 mg - 220,00 mg sex hormone 0.25 mg - 5.00 mg 2. The anti-asthmatic medicament of claim 1, wherein the sex hormone is methandrostenol An anti-asthmatic medicament according to claim 1, characterized in that the sex hormone is diethylstilbestrol propionate